Spero Therapeutics, which is developing treatments for drug-resistant bacterial infections, raised $77 million by offering 5.5 million shares at $14, the low end of the range of $14 to $16. It had previously filed to offer 5.0 million shares. Insiders indicated an interest in purchasing $30 million (39% of the deal) on the offering. Spero Therapeutics plans to list on the Nasdaq under the symbol SPRO. BofA Merrill Lynch, Cowen & Company and Stifel acted as lead managers on the deal.
